SCHEMBL24766469

SCHEMBL24766469

Clc1cc(-c2ccnn2PI)nc(N2CCOCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.40
▸ CYP1A2 P05177 3/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CNR2 P34972 2/20 0.39
▸ SMG1 Q96Q15 2/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ PIK3CA P42336 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ MTOR P42345 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ CDK1 P06493 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24766059 0.81 ATR (0.47) MAPTCYP1A2KMT2ANPC1RAB9A
SCHEMBL24766288 0.76 RAF1 (0.45) MAPTCYP1A2KMT2ANPC1RAB9A
SCHEMBL17204101 0.73 MAPT (0.61) MAPTCYP1A2KMT2ANPC1RAB9A
SCHEMBL24766468 0.73 ATR (0.58) —
SCHEMBL24766568 0.71 ATR (0.57) —
SCHEMBL29434142 0.70 CDK1 (0.52) MAPTCYP1A2CYP2D6SMG1PIK3CA
SCHEMBL24766835 0.70 CDK1 (0.52) MAPTCYP1A2CYP2D6SMG1PIK3CA
SCHEMBL29434159 0.69 MAPT (0.65) MAPTCYP1A2KMT2ANPC1RAB9A
SCHEMBL29434160 0.69 MAPT (0.65) MAPTCYP1A2KMT2ANPC1RAB9A
SCHEMBL971891 0.69 MAPT (0.65) MAPTCYP1A2KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407737-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407737-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF MAPT 2859/4885CYP1A2 4302/4885KMT2A 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback